Search results for "BLOOD EOSINOPHILS"

showing 4 items of 4 documents

Iperreattività bronchiale aspecifica in pazienti monosensibili con rinite allergica: variazioni stagionali in rapporto alle IgE sieriche totali ed ag…

2005

Introduction: The significance of the association between allergic rhinitis and abnormal airway responsiveness is unclear. For this reason, we have studied, in patients with seasonal allergic rhinitis, non specific bronchial hyperreactivity, total serum IgE and blood eosinophils, with reference to the responsible allergen, during and out of the pollen season. Materials and methods: Fourty-nine, non-smoking patients, living in Palermo, with clinical diagnosis of allergic rhinitis, skin prick tests and specific serum IgE mono-sensitive to pollen allergens, were enrolled in the study. Twenty patients suffered from seasonal rhinitis to Parietaria pollen, 15 patients to Graminacee pollen and 14 …

Blood eosinophils countNon specific bronchial hyperreactivitySeasonal allergic rhinitiTotal serum IgEPC20-FEV1
researchProduct

Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

2021

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), …

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtymedicine.drug_classSevere asthmaEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPersistence (computer science)03 medical and health sciences0302 clinical medicineInternal medicineBronchodilatorallergic asthma blood eosinophil bronchodilator reversibility lung function decline severe asthma salbutamolForced Expiratory VolumemedicineSettore MED/10Immunology and AllergyHumans030212 general & internal medicineBlood eosinophilLungGenetics (clinical)Lung functionBronchodilator Agentallergic asthma; blood eosinophil; bronchodilator reversibility; lung function decline; severe asthma; salbutamol; bronchodilator agents; eosinophils; forced expiratory volume; humans; lung; airway obstruction; asthmabusiness.industrylung function declineAirway obstructionmedicine.diseaseAsthmaBronchodilator AgentsAirway ObstructionEosinophilsbronchodilator reversibility030228 respiratory systemsalbutamolSalbutamolBlood eosinophilsbusinessallergic asthmamedicine.drugHumanblood eosinophilThe clinical respiratory journalREFERENCES
researchProduct

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

2017

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.METHODSWe performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were …

medicine.medical_specialtyPARALLEL-GROUPPopulationPlacebo-controlled studyPNEUMONIA RISKPlaceboPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMaintenance therapyInternal medicineEosinophilicmedicineINHALED FLUTICASONE FUROATE030212 general & internal medicineeducationCOPDeducation.field_of_studyIntention-to-treat analysisCOPD ASSESSMENT TESTSPUTUM EOSINOPHILIAbusiness.industryGeneral MedicineRANDOMIZED CONTROLLED-TRIALBLOOD EOSINOPHILSmedicine.diseaseSECONDARY ANALYSIS030228 respiratory systemImmunologybusinessMepolizumabmedicine.drug
researchProduct

Dažādu astmas vērtēšanas parametru korelācija: plaušu funkcija (FEV), NO izelpas gaisā (FeNO) un eozinofīlu skaits asinīs.

2018

Mūsu pētījuma galvenais mērķis bija novērtēt korelāciju starp dažādiem astmas vērtēšanas parametriem, piemēram, forsētās izelpas tilpumu pirmās sekundes laikā (FEV1), frakcionēto slāpekļa oksīdu slāpekļa oksīdu (FeNO) un eozinofilo leikocītu skaitu venozās asinīs pacientiem ar bronhiālo astmu, lietojot inhalējamo kortikosteroīdu ārstēšanā. Pētījuma tika iekļauti 180 pacienti vecumā no 18 līdz 75 gadiem, ar astmas diagnozi un atgriezenisku obstrukciju, kuri tika ārstēti ar 2.-4. ārstēšanas soli atbilstoši Globālās astmas iniciatīvas (GINA) vadlīnijām. Pētījuma populācijā bija 108 sievietes un 72 vīrieši. No kuriem 114 bija nesmēķētāji, 30 bijušie smēķētāji un 36 smēķētāji. 108 pacienti jeb 6…

FEV1CORRELATIONFeNOBlood eosinophilsMedicīna
researchProduct